Malignant hyperthermia susceptibility

Denboroug, M.A., Phil, D. (1985). Current concepts of the etiology and treatment of malignant hyperthermia susceptible patients (letter). Anesthesiology 62,99. 

Huckell, F.V. (1986). Cardiac manifestations of malignant hyperthermia susceptibility. Circulation 58,... 

Table 4. CACNA1S (Cavl.l, als) Functional results for mutations associated with HypoPP = Hypokalemic periodic paralysis and MHS = Malignant hyperthermia susceptibility (only those HypoPP mutations with functional data are listed)...

Ducreux, S., Zorzato, F., Muller, C., Sewry, C., Muntoni, F., Quinlivan, R., Restagno, G., Girard, T., and Treves, S. (2004). Effect of Ryanodine Receptor Mutations on Interleukin-6 Release and Intracellular Calcium Homeostasis in Human Myotubes from Malignant Hyperthermia-Susceptible Individuals and Patients Affected by Central Core Disease. J Biol Chem 279(42) 43838 16. 

Hackl, W., Winkler, M., Mauritz, W., Sporn, P., and Steinbereithner, K. (1991). Muscle Biopsy for Diagnosis of Malignant Hyperthermia Susceptibility in Two Patients with Severe Exercise-Induced Myolysis. Br J Anaesth 66(1) 138—40. 

Monnier, N., Procaccio, V., Stieglitz, P., and Lunardi, J. (1997). Malignant -Hyperthermia Susceptibility Is Associated With Mutation of the alpha 1-Subunit of the Human Dihydropyridine-Sensitive L-Type Voltage-Dependent Calcium-Channel Receptor in Skeletal Muscle. Am. J. Hum. Genet. 60 1316—25. 

Sambuughin, N., Holley, H., Muldoon, S., Brandom, B. W., de Bantel, A. M., Tobin, J. R., Nelson, T. E., and Goldfarb, L. G. (2005). Screening of the Entire Ryanodine Receptor Type 1 Coding Region for Sequence Variants Associated with Malignant Hyperthermia Susceptibility in the North American Population." Anesthesiology 102(3) 515—21. 

Kara Y, Kato A, Horikawa H, Kato Y, Ichiyanagi K. [Postoperative respiratory depression thought to be due to oral dantrolene pretreatment in a malignant hyperthermia-susceptible patient.] Masui 1988 37(4) 483-7. 

Fiege M, Wappler F, Scholz J, Weisshorn R, von Richthofen V, Schulte am Esch J. Effects of the phospho-diesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients. J Chn Anesth 2000 12(2) 123-8. 

Brooks JH. Midazolam in a malignant hyperthermia-susceptible patient. Anesthesiology 1989 70(l) 167-8. 

Allen GC, Rosenberg H. Malignant hyperthermia suscept-ibihty in adult patients with masseter muscle rigidity. Can J Anaesth 1990 37(l) 31-5. 

Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility. Anesth Analg 1986 65(2) 161. ... 

Ranklev E, Henriksson KG, Fletcher R, Germundsson K, Oldfors A, Kalimo H. Clinical and muscle biopsy findings in malignant hyperthermia susceptibility. Acta Neurol Scand 1986 74(6) 452-9. 

Wappler F, Anetseder M, Baur CP, et al. Multicenter evaluation of in vitro contracture testing with bolus administration of 4-chloro-w-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesth 2003 20 528—536. 

---